Cover Image
市場調查報告書

CXC趨化素受體類型4 (Fusin/白血球來源、七跨膜區受體、脂多醣相關蛋白質3、基質細胞來源因子1受體、CD184、CXCR4):開發中產品分析

C-X-C Chemokine Receptor Type 4 (FB22/Fusin/HM89/LCR1/Leukocyte Derived Seven Transmembrane Domain Receptor/Lipopolysaccharide Associated Protein 3/Stromal Cell Derived Factor 1 Receptor/NPYRL/CD184/CXCR4) - Pipeline Review, H1 2018

出版商 Global Markets Direct 商品編碼 363566
出版日期 內容資訊 英文 104 Pages
訂單完成後即時交付
價格
Back to Top
CXC趨化素受體類型4 (Fusin/白血球來源、七跨膜區受體、脂多醣相關蛋白質3、基質細胞來源因子1受體、CD184、CXCR4):開發中產品分析 C-X-C Chemokine Receptor Type 4 (FB22/Fusin/HM89/LCR1/Leukocyte Derived Seven Transmembrane Domain Receptor/Lipopolysaccharide Associated Protein 3/Stromal Cell Derived Factor 1 Receptor/NPYRL/CD184/CXCR4) - Pipeline Review, H1 2018
出版日期: 2018年02月20日 內容資訊: 英文 104 Pages
簡介

本報告提供全球各國的CXC趨化素受體類型4 (別名Fusin/白血球來源、七跨膜區受體,脂多醣相關蛋白質3,為您概述為以下內容基質細胞來源因子1受體,CD184,CXCR4) 治療藥的開發中產品的開發情形相關分析,產品開發、上市的最新趨勢,及臨床實驗的各階段的產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等資訊。

目錄

  • 簡介
    • 分析範圍
  • CXC趨化素受體類型4 (Fusin/白血球來源、七跨膜區受體,脂多醣相關蛋白質3,基質細胞來源因子1受體,CD184,CXCR4)的概要
  • 治療藥的開發情形
    • 臨床實驗的各階段
    • 各治療領域
    • 各症狀
  • 開發中產品的概要
    • 後期階段的產品
    • 初期階段的產品
    • 不明階段的產品
  • 各企業開發中的治療藥
  • 各大學、研究機關開發中的治療藥
  • 治療藥的評估
    • 單劑治療藥/並用治療藥的情況
    • 各作用機制
    • 各投藥法
    • 各分子類型
  • 開發治療藥的企業
    • AdAlta Pty Ltd.
    • Ambrx, Inc.
    • Anchor Therapeutics, Inc.
    • Biokine Therapeutics Ltd.
    • BioLineRx, Ltd.
    • Bristol-Myers Squibb Company
    • Eli Lilly and Company
    • Globavir Biosciences, Inc.
    • GlycoMimetics, Inc.
    • NeED Pharma s.r.l.
    • Pharis Biotec GmbH
    • Polyphor Ltd.
    • Sanofi
    • TaiGen Biotechnology Co., Ltd.
    • Upsher-Smith Laboratories, Inc.
    • X4 Pharmaceuticals, Inc.
  • 藥物簡介
  • 開發暫停的產品
  • 開發中止的產品
  • 值得注意的最新趨勢、新聞稿
  • 附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC1296TDB

Title:
C-X-C Chemokine Receptor Type 4
(FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) - Pipeline Review, H1 2018.

Summary:

C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) - C-X-C chemokine receptor type 4 or CD184 is a protein encoded by the CXCR4 gene.

It is a receptor for the C-X-C chemokine CXCL12/SDF-1 that transduces a signal by increasing intracellular calcium ion levels and enhancing MAPK1/MAPK3 activation, extracellular ubiquitin, leading to enhanced intracellular calcium ions and reduced cellular cAMP levels. It is involved in hematopoiesis and in cardiac ventricular septum formation. It also plays an essential role in vascularization of the gastrointestinal tract, probably by regulating vascular branching and/or remodeling processes in endothelial cells.

C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) pipeline Target constitutes close to 24 molecules. Out of which approximately 20 molecules are developed by companies and remaining by the universities/institutes.

The molecules developed by companies in Phase III, Phase II, Phase I, IND/CTA Filed and Preclinical stages are 3, 4, 3, 1 and 9 respectively. Similarly, the universities portfolio in Phase I and Preclinical stages comprises 1 and 3 molecules, respectively.

Report covers products from therapy areas Oncology, Cardiovascular, Immunology, Infectious Disease, Respiratory, Gastrointestinal, Genetic Disorders, Genito Urinary System And Sex Hormones, Hematological Disorders, Male Health, Ophthalmology and Women's Health which include indications Multiple Myeloma (Kahler Disease), Non-Hodgkin Lymphoma, Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Colon Cancer, Human Immunodeficiency Virus (HIV) Infections (AIDS), Melanoma, Non-Small Cell Lung Cancer, Pancreatic Cancer, Small-Cell Lung Cancer, Solid Tumor, Uveal Melanoma, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Adenocarcinoma Of The Gastroesophageal Junction, Allergic Asthma, Aplastic Anemia, Breast Cancer, Chronic Lymphocytic Leukemia (CLL), Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Critical Limb Ischemia, Erectile Dysfunction, Glioblastoma Multiforme (GBM), Hematopoietic Stem Cell Transplantation, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Idiopathic Pulmonary Fibrosis, Inflammation, Intimal Hyperplasia, Kidney Fibrosis, Liver Cancer, Metastatic Adenocarcinoma of The Pancreas, Metastatic Breast Cancer, Metastatic Hepatocellular Carcinoma (HCC), Metastatic Melanoma, Metastatic Prostate Cancer, Myelodysplastic Syndrome, Myocardial Infarction, Neuroblastoma, Non-Alcoholic Steatohepatitis (NASH), Pancreatic Ductal Adenocarcinoma, Prostate Cancer, Recurrent Glioblastoma Multiforme (GBM), Renal Cell Carcinoma, Stroke, Thrombocytopenia, Vasomotor Symptoms of Menopause (Hot Flashes), Waldenstrom Macroglobulinemia, Wet (Neovascular / Exudative) Macular Degeneration, WHIM Syndrome (Warts, Hypogammaglobulinemia and Infections and Myelokathexis).

The latest report C-X-C Chemokine Receptor Type 4 - Pipeline Review, outlays comprehensive information on the C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The report provides a snapshot of the global therapeutic landscape for C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4)
  • The report reviews C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) targeted therapeutics and enlists all their major and minor projects
  • The report assesses C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) targeted therapeutics

Reasons to buy:

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) - Overview
    • C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) - Therapeutics Development
    • Products under Development by Stage of Development
    • Products under Development by Therapy Area
    • Products under Development by Indication
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) - Therapeutics Assessment
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) - Companies Involved in Therapeutics Development
    • AdAlta Ltd
    • Ambrx Inc
    • BioLineRx Ltd
    • Bristol-Myers Squibb Co
    • Eli Lilly and Co
    • GlycoMimetics Inc
    • Pfizer Inc
    • Pharis Biotec GmbH
    • Polyphor Ltd
    • TaiGen Biotechnology Co Ltd
    • Upsher-Smith Laboratories Inc
    • X4 Pharmaceuticals Inc
  • C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) - Drug Profiles
    • AD-114 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ALB-408 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AM-3114 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • balixafortide - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BL-8040 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • burixafor - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GMI-1359 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HPH-112 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HPH-196 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HPH-211 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • hz-515H7 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LY-2510924 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibody Conjugate to Antagonize CXCR4 for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PF-06747143 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • POL-5551 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Protein to Agonize CXCR4 for Inflammation - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PTX-9908 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Q-122 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Recombinant Protein to Agonize CXCR4 for Erectile Dysfunction - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Recombinant Protein to Antagonize CXCR4 for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ulocuplumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • USL-311 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • X-4P001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • X-4P002 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) - Dormant Products
  • C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) - Discontinued Products
  • C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) - Product Development Milestones
    • Featured News & Press Releases
      • Jan 23, 2018: BioLineRx Presents Preclinical Data at ASCO-SITC Showing BL-8040 Prolongs Survival by Mediating Tumor Infiltration of Antigen-Specific T-cells
      • Jan 17, 2018: BioLineRx Announces Partial Monotherapy Results from Phase 2a COMBAT Study in Pancreatic Cancer
      • Jan 16, 2018: Researcher looks to next generation antibody treatment for Chronic Kidney Disease
      • Jan 08, 2018: AdAlta to present at the Biotech Showcase in San Francisco
      • Dec 21, 2017: BioLineRx Announces Initiation of Phase III GENESIS Trial in Stem-Cell Mobilization for Autologous Transplantation in Multiple Myeloma Patients
      • Dec 11, 2017: First Clinical Data for X4P-001-RD Demonstrated Promising Activity in Patients with WHIM Syndrome, a Primary Immunodeficiency Disease
      • Dec 07, 2017: NHMRC $768,000 Grant for Development of AD-114 in Chronic Kidney Disease
      • Dec 04, 2017: BioLineRx Reports Overall Survival Results From Long-Term Follow-Up of Phase IIa Trial in r/r AML
      • Nov 22, 2017: AdAlta gets commercial-ready after pre-clinical safety studies show promising results
      • Nov 20, 2017: BioLineRx Announces Partial Results of BL-8040 COMBAT Study Accepted for Presentation at ASCO 2018 Gastrointestinal Cancers Symposium
      • Nov 16, 2017: AdAlta receives grant of key Australian patent for AD-114
      • Nov 16, 2017: First Clinical Data for X4P-001-RD Demonstrating Preliminary Activity in Patients with WHIM Syndrome will be Presented at American Society for Hematology Annual Meeting
      • Nov 13, 2017: AdAlta to present at Anti-Fibrotic Drug Development Summit in Boston
      • Nov 10, 2017: X4 Pharmaceuticals Presents Clinical Data Demonstrating Immune Activation Through CXCR4 Pathway with X4P-001-IO
      • Nov 03, 2017: First Clinical Data from Combination of X4P-001-IO and Keytruda (pembrolizumab) in Patients with Melanoma Will Be Presented at the Society for Immunotherapy of Cancer Annual Meeting
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development by Stage of Development, H1 2018
  • Number of Products under Development by Therapy Areas, H1 2018
  • Number of Products under Development by Indications, H1 2018
  • Number of Products under Development by Indications, H1 2018 (Contd..1), H1 2018
  • Number of Products under Development by Indications, H1 2018 (Contd..2), H1 2018
  • Number of Products under Development by Companies, H1 2018
  • Products under Development by Companies, H1 2018
  • Products under Development by Companies, H1 2018 (Contd..1), H1 2018
  • Products under Development by Companies, H1 2018 (Contd..2), H1 2018
  • Products under Development by Companies, H1 2018 (Contd..3), H1 2018
  • Number of Products under Investigation by Universities/Institutes, H1 2018
  • Products under Investigation by Universities/Institutes, H1 2018
  • Number of Products by Stage and Mechanism of Actions, H1 2018
  • Number of Products by Stage and Route of Administration, H1 2018
  • Number of Products by Stage and Molecule Type, H1 2018
  • Pipeline by AdAlta Ltd, H1 2018
  • Pipeline by Ambrx Inc, H1 2018
  • Pipeline by BioLineRx Ltd, H1 2018
  • Pipeline by Bristol-Myers Squibb Co, H1 2018
  • Pipeline by Eli Lilly and Co, H1 2018
  • Pipeline by GlycoMimetics Inc, H1 2018
  • Pipeline by Pfizer Inc, H1 2018
  • Pipeline by Pharis Biotec GmbH, H1 2018
  • Pipeline by Polyphor Ltd, H1 2018
  • Pipeline by TaiGen Biotechnology Co Ltd, H1 2018
  • Pipeline by Upsher-Smith Laboratories Inc, H1 2018
  • Pipeline by X4 Pharmaceuticals Inc, H1 2018
  • Dormant Products, H1 2018
  • Dormant Products, H1 2018 (Contd..1), H1 2018
  • Dormant Products, H1 2018 (Contd..2), H1 2018
  • Dormant Products, H1 2018 (Contd..3), H1 2018
  • Dormant Products, H1 2018 (Contd..4), H1 2018
  • Discontinued Products, H1 2018

List of Figures

  • Number of Products under Development by Stage of Development, H1 2018
  • Number of Products under Development by Therapy Areas, H1 2018
  • Number of Products under Development by Top 10 Indications, H1 2018
  • Number of Products by Mechanism of Actions, H1 2018
  • Number of Products by Stage and Mechanism of Actions, H1 2018
  • Number of Products by Routes of Administration, H1 2018
  • Number of Products by Stage and Routes of Administration, H1 2018
  • Number of Products by Molecule Types, H1 2018
  • Number of Products by Stage and Molecule Types, H1 2018
Back to Top